Oncotelic Therapeutics (OTCMKTS:OTLC – Get Free Report) and VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.
Profitability
This table compares Oncotelic Therapeutics and VistaGen Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oncotelic Therapeutics | N/A | 183.45% | 117.54% |
| VistaGen Therapeutics | -5,487.01% | -133.02% | -105.79% |
Valuation and Earnings
This table compares Oncotelic Therapeutics and VistaGen Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oncotelic Therapeutics | $70,000.00 | 289.56 | $249.28 million | $0.59 | 0.08 |
| VistaGen Therapeutics | $1.27 million | 22.68 | -$69.68 million | ($1.83) | -0.38 |
Oncotelic Therapeutics has higher earnings, but lower revenue than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Oncotelic Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Oncotelic Therapeutics has a beta of -0.34, indicating that its stock price is 134% less volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.
Insider and Institutional Ownership
78.4% of VistaGen Therapeutics shares are owned by institutional investors. 39.2% of Oncotelic Therapeutics shares are owned by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Oncotelic Therapeutics and VistaGen Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oncotelic Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| VistaGen Therapeutics | 1 | 4 | 0 | 0 | 1.80 |
VistaGen Therapeutics has a consensus target price of $0.95, suggesting a potential upside of 35.33%. Given VistaGen Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe VistaGen Therapeutics is more favorable than Oncotelic Therapeutics.
Summary
Oncotelic Therapeutics beats VistaGen Therapeutics on 8 of the 13 factors compared between the two stocks.
About Oncotelic Therapeutics
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.
About VistaGen Therapeutics
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
Receive News & Ratings for Oncotelic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncotelic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
